52 results on '"Quinn, D.I."'
Search Results
2. Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101
3. 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
4. 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101
5. 651O Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
6. ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
7. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
8. 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC)
9. 746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
10. Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer
11. Activity of the FGFR1–3 inhibitor infigratinib in patients with upper tract urothelial carcinoma and urothelial carcinoma of the bladder: Latest efficacy findings and comprehensive genomic profiling/cell-free DNA data
12. Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
13. Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
14. Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
15. A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
16. cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
17. Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma
18. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
19. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
20. Phase I Trial of SBRT to the Prostate Bed Following Prostatectomy
21. Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
22. Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045
23. Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel
24. Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
25. Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564
26. Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421
27. The evolution of chemotherapy for the treatment of prostate cancer
28. Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer
29. Phase II California cancer consortium trial of gemcitabine-eribulin combination (ge) in cisplatin ineligible patients (pts) with metastatic urothelial carcinoma (mUC): Efficacy report (NCI-9653; 1UM1CA186717, NO1-CM-2011-00038)
30. Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc)
31. KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC)
32. Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial
33. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions
34. A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI)
35. Bone biomarkers and overall survival (OS) in men with castrate resistant prostate cancer (CRPC) and skeletal metastases: Updated results from SWOG 0421, a phase III trial of docetaxel +/- atrasentan
36. P0084 Eribulin in patients with advanced urothelial cancer and previously treated with platinum and anti-microtubule chemotherapy: A phase 2 California Cancer Consortium trial
37. Anzup 1302: a Randomised Phase 3 Trial of Accelerated Versus Standard Bep Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours (P3Bep)
38. Stride, a Randomized, Phase 2, Open-Label Study of Sipuleucel-T with Concurrent Vs Sequential Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
39. Carboplatin's fourth decade: still searching for its sweet spot
40. MC13-0020 Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors
41. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore
42. Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: ‘plus or minus’ may be a minus
43. Updated Analysis of a Combination Herbal Supplement Trial in Biochemically Recurrent Prostate Cancer
44. Antigen Presenting Cell (APC) Activation in Sipuleucel-T: Is Activation Increased in Earlier Prostate Cancer Disease States?
45. Gemcitabine, Oxaliplatin, and Paclitaxel (GOT) on a 2-Weekly Schedule in Patients (PTS) with Refractory Germ Cell Carcinoma: A Phase II Study Conducted at the University of Southern California
46. Sequential Androgen Deprivation and Chemotherapy in Metastatic Prostate Cancer: Discordant Responses in Pilot Study Suggest an Opportunity for Individualized Therapy
47. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer
48. 7043 POSTER A Phase l/lI Trial of AN-152 in Castration- and Taxane-Resistant Prostate Cancer
49. 7163 Phase II study of eribulin (Halichondrin B analogue, E7389) in patients with advanced urothelial cancer (AUC) – California Cancer Consortium led NCI/CTEP-sponsored trial
50. 7027 Interim results of a phase II trial of oxaliplatin and pemetrexed as 2nd/3rd line therapy in castration resistant prostate cancer (CRPC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.